Goldman Sachs Group Inc Tcr2 Therapeutics Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$1.0 - $1.62 $956 - $1,548	-956 Reduced 8.16%	10,765 $16,000
Q1 2023 May 11, 2023	SELL	$1.0 - $1.62 $956 - $1,548	-956 Reduced 8.16%	10,765 $16,000
Q4 2022 May 14, 2024	SELL	$0.83 - $1.44 $23,400 - $40,597	-28,193 Reduced 70.63%	11,721 $11,000
Q4 2022 Feb 13, 2023	SELL	$0.83 - $1.44 $23,400 - $40,597	-28,193 Reduced 70.63%	11,721 $11,000
Q3 2022 May 14, 2024	SELL	$1.86 - $3.75 $81,006 - $163,320	-43,552 Reduced 52.18%	39,914 $72,000
Q3 2022 Nov 10, 2022	SELL	$1.86 - $3.75 $81,006 - $163,320	-43,552 Reduced 52.18%	39,914 $0
Q2 2022 May 14, 2024	BUY	$2.11 - $2.94 $176,113 - $245,390	83,466 New	83,466 $242,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $180,052 - $250,879	-85,333 Reduced 50.55%	83,466 $242,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $417,516 - $819,375	-173,965 Reduced 50.75%	168,799 $466,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $1.2 Million - $2.19 Million	262,897 Added 329.17%	342,764 $1.6 Million
Q3 2021 Nov 10, 2021	BUY	$8.44 - $18.35 $674,077 - $1.47 Million	79,867 New	79,867 $680,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.